WIN378

About Windward Bio

Windward Bio is a newly launched, well-funded private biotech with a clear focus on immunology. The company emerged in January 2025 with a substantial $200M Series A financing and is led by a seasoned executive team with a strong track record of company creation and exits. Its strategy centers on engineering long-acting antibodies against established targets like TSLP and IL-13, with two clinical-stage programs aimed at improving dosing convenience and efficacy in diseases such as asthma and COPD. The company is positioned to advance its pipeline rapidly, leveraging its team's deep development and commercialization expertise.

Therapeutic Areas